Get to Know VeraSci

Your Thought Partner in Scientific Discovery

As clinical trials grow in scope and complexity, VeraSci provides the scientific and operational clarity needed for optimal trial performance and accelerated drug development. We are a global clinical and cognitive assessment services and technology company devoted to applying rigorous standards for key endpoints in multi-site clinical trials in many different indications.

With an unwavering commitment to data integrity, our work not only supports the scientific investigation of novel therapies—we’re driving significant improvements to the overall quality of clinical trials and enhancing the capacity of research to transform global healthcare. Founded in 2004 as NeuroCog Trials (NCT), VeraSci is a privately held, certified woman-owned business, headquartered in Durham, North Carolina.

Meet the Leadership Team Behind VeraSci

With unparalleled experience in clinical outcomes and neurocognitive measurement, a proven track record in supporting trial design, implementation, and evaluation, our team delivers expert guidance and data you can trust.

 

Luca Pani, MD

VP, Regulatory Strategy and Market Access Innovation
Read Bio
Luca Pani, MD

Luca Pani, MD

VP, Regulatory Strategy and Market Access Innovation

Dr. Luca Pani is former Director General of the Italian Medicines Agency (AIFA) and a globally recognized expert in psychiatry, pharmacology and molecular biology. As Vice President for Regulatory Strategy and Market Access Innovation, Dr. Pani guides the company’s development of innovative solutions for clinical trials methodologies and health value outcomes. During his tenure as Director General of AIFA, Dr. Pani pioneered several new approaches to drug approval, pricing, and reimbursement strategies by using advanced informatics to follow and certify real-world data. These models have now been adopted in many other countries. As a European regulator, Dr. Pani has been a leading figure for approval and scientific advice for CNS products and served as Chair of both the European Union Board Telematics Committee and of the European Risk Management Strategy Facilitation Group. He has authored or co-authored hundreds of publications and served on the editorial boards of many scientific journals, including Clinical Neuropsychiatry. He is Professor of Clinical Psychiatry at the University of Miami. Dr. Pani earned his medical degree from the University of Cagliari, psychiatry degree from the University of Naples and completed post-doctoral training in molecular biology and pharmacology at the University of Illinois at Chicago and Georgetown University.

Kathleen Anne Welsh-Bohmer, PhD, ABPP

VP, Neurodegenerative Disorders
Read Bio
Kathleen Anne Welsh-Bohmer, PhD, ABPP

Kathleen Anne Welsh-Bohmer, PhD, ABPP

VP, Neurodegenerative Disorders

For more than 25 years, Dr. Kathleen Anne Welsh-Bohmer’s research activities have been focused around developing effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring in later life. As one of the true leaders in Alzheimer’s Disease scientific research, Dr. Welsh-Bohmer brings vast expertise to VeraSci. As Vice President for Neurodegenerative Disorders at VeraSci, she leads a team of scientists and operational experts in developing new tools for assessing cognitive and clinical changes and supporting clinical trials in MCI, Alzheimer’s disease and other neurological and age-related disorders. Most recently, Dr. Welsh-Bohmer provided oversight of the neuropsychology scientific operations of a Phase III global clinical trial to delay the onset of Alzheimer’s disease entitled the “TOMMORROW” study. The methods her team developed for this study filled an information void and had implications for accelerating global clinical trials in Alzheimer’s disease prevention. Dr. Welsh-Bohmer’s work as Director of the Joseph and Kathleen Bryan Alzheimer’s Disease Research Center (Bryan ADRC) at Duke University Medical Center was centered around discovering the biological basis of Alzheimer’s disease and developing methods to enhance early diagnosis and speed drug discovery. In addition to her current work at VeraSci, she serves as the Director of Alzheimer’s Disease Clinical Trials within the Duke Clinical Research Institute and is a Professor of Psychiatry with a secondary appointment in the Department of Neurology at Duke University. Therapeutic Focus: Alzheimer's Disease

Alexandra Atkins, PhD

VP, Scientific Development
Read Bio
Alexandra Atkins, PhD

Alexandra Atkins, PhD

VP, Scientific Development

Dr. Alexandra Atkins is a psychologist and cognitive neuroscientist with expertise in cognitive assessment, clinical trial methodology, and the cognitive neuroscience of memory. Over the past seven years, she has worked alongside Dr. Keefe to spearhead the development of valid and reliable assessments of cognition and function for use in CNS clinical trials and clinical practice. As Vice President of Scientific Development, Dr. Atkins provides scientific oversite to VeraSci project teams across CNS indications and serves as PI on several ongoing technology-based research initiatives supported by the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA). Dr. Atkins has received National Research Service Awards from both NIMH and NIA to support research using cognitive testing in conjunction with functional neuroimaging techniques to examine the cognitive and neural mechanisms of memory distortion and executive functioning. Her current interests include the strategic use of innovative technology to support valid clinical ratings in clinical trials and improving assessment of subtle functional impairments in prodromal MCI/AD. Dr. Atkins earned her PhD in psychology from the University of Michigan and completed her research fellowship at Duke University’s Center for Cognitive Neuroscience. Therapeutic Focus: CNS Disorders

William P. Horan, PhD

VP, Clinical Science
Read Bio
William P. Horan, PhD

William P. Horan, PhD

VP, Clinical Science

As a Vice President of Clinical Science, Dr. Horan uses his expertise in cognition, social neuroscience, and symptom assessment to provide scientific and operational support for clinical trials in psychiatric disorders. Prior to joining VeraSci, Dr. Horan was Professor-in-Residence in the Department of Psychiatry & Biobehavioral Sciences at UCLA and Chief of the Psychosis Section at the VA Greater Los Angeles Healthcare System. Over the past 20 years, his clinical research has focused on understanding and developing treatments for motivational, social cognitive, and neurocognitive disturbances that impact functional outcomes in schizophrenia and other neuropsychiatric conditions. Specific interests include negative symptoms, translational affective and social cognitive neuroscience research, and development of novel physiological and behavioral tasks for use as endpoints in clinical trials. His research has been funded by NIMH, VA, and foundation grants, and he served as a Principal Investigator in the NIMH Collaboration to Advance Negative Symptom Assessment in Schizophrenia. He is on the Editorial Boards of Schizophrenia Bulletin, Schizophrenia Research: Cognition, and Journal of Abnormal Psychology (Associate Editor). He has over 130 peer-reviewed articles and has been recognized as a Thomson Reuters Highly Cited Researcher (Top 1% in Psychiatry/ Psychology). Therapeutic Focus: Schizophrenia

Mark Skeen, MD

Senior Medical Scientist
Read Bio
Mark Skeen, MD

Mark Skeen, MD

Senior Medical Scientist

Dr. Mark Skeen is a Senior Medical Scientist at VeraSci. Dr. Skeen is a neurologist with broad clinical training and experience. He is board certified in Internal Medicine, Neurology, and Clinical Neurophysiology and has broad clinical experience in neurology clinical trials in several disease states. He has over 30 years of clinical experience from general internal medicine to neurology subspecialty care and for the past 15 years his focus has been multiple sclerosis and related autoimmune conditions. He is recognized as a thought leader in multiple sclerosis and has been recognized for both clinical and teaching expertise. Dr. Skeen also serves as an Associate Professor of Neurology at Duke University Medical Center and is the head of the division of Multiple Sclerosis and Neuroimmunology. He is a Fellow of the American College of Physicians and the American Academy of Neurology. He has many longstanding partnerships throughout the pharmaceutical industry and brings a distinctly clinical neurologic perspective to VeraSci. Therapeutic Focus: Multiple Sclerosis

Heather Snyder, PhD

Senior Director, Neurosciences
Read Bio
Heather Snyder, PhD

Heather Snyder, PhD

Senior Director, Neurosciences

Dr. Heather Snyder is Senior Director of Neurosciences at VeraSci. She provides scientific and clinical input to the development of training materials for clinical assessments utilized in clinical trials for neurologic and psychiatric indications. Dr. Snyder and the scientific team also provide consultation regarding protocol design and outcome measures, as well as clinical development pathways. Additional responsibilities include provision of scientific input for data review and analyses, business development, and development of assessments on VeraSci’s eCOA platform, Pathway. Before joining VeraSci, Dr. Snyder spent over 13 years in program leadership roles for neuroscience clinical development, within pharmaceutical clinical research departments. As such, she held positions within key biopharmaceutical companies, including Astra Merck Inc., Astra AB, Merck & Co., Cephalon, Inc., and Astra-Zeneca. Dr. Snyder led development programs for following neuroscience indications: Generalized Anxiety Disorder, Post-traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder, Major Depressive Disorder, Multiple Sclerosis, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. Dr. Snyder obtained her BA in Philosophy from Georgetown University, and her PhD in Clinical Psychology, with a focus in Neuropsychology, from George Mason University. Her Post-Doctoral Fellowship work was done at the University of Pennsylvania. Therapeutic Focus: Parkinson's Disease, Multiple Sclerosis, Rare & Orphan Diseases

Adam W. Vaughan, PhD

Senior Director, Psychological Assessments
Read Bio
Adam W. Vaughan, PhD

Adam W. Vaughan, PhD

Senior Director, Psychological Assessments

Dr. Adam Vaughan is Senior Director of Psychological Assessments at VeraSci. He is one of our project managers in the VeraSci Innovation Lab, which focuses on R&D of our proprietary tools. Adam also represents our company at various conferences and works on our rare and orphan disease studies. Prior to joining the team at VeraSci, Adam worked as a school psychologist in the public-school system, assessing and evaluating a full range of children and adolescents with special needs and behavioral issues. Adam received his bachelor’s in Psychology from the University of North Carolina at Chapel Hill and his Doctoral Degree in Psychology and Psychometrics from Auburn University. Therapeutic Focus: Childhood Disorders, Rare & Orphan Diseases

Antonio Hernandez, PsyD

Senior Clinical Director, Neurodegenerative Disorders
Read Bio
Antonio Hernandez, PsyD

Antonio Hernandez, PsyD

Senior Clinical Director, Neurodegenerative Disorders

Dr. Antonio Hernandez is Senior Clinical Director of Neurodegenerative Disorders at VeraSci. He participates in the development and use of innovative new technologies that assess cognition in Alzheimer’s disease and aging. He also assists in developing and validating new test batteries, reviewing, analyzing and interpreting cognitive test data, and oversees neurocognitive rater certification and data quality control for multi-site pharmaceutical company trials. Other key activities include development of strategic objectives that support the company’s research and development strategies along with establishing strategic partnerships and alliances. Dr. Hernandez came to VeraSci with over 15 years of clinical research experience across several CNS therapeutic areas. His vast industry experience, exceptional degree of sustained ingenuity, creativity and resourcefulness has been instrumental in shaping the course of many clinical trials in CNS. He has a deep understanding of the clinical as well as operational challenges facing global clinical trials today and has worked closely within multidisciplinary team environments, including business development and marketing. Fluent in Spanish, he has also contributed to the translation and development of eCOA in the assessment of dementia and pre-MCI subjects. Therapeutic Focus: Alzheimer's Disease

Timothy Clayton

VP, Product Development
Read Bio
Timothy Clayton

Timothy Clayton

VP, Product Development

Tim Clayton has been developing and delivering successful software products, devices and data solutions for over 25 years, with more than 13 years focused in clinical research and medical device industries. His deep knowledge of C-DISC data standards, clinical data management processes, database, cloud and software development technologies was acquired through hands on building and management of clinical data warehouses, analytics and B2B solutions supporting the world’s top pharmaceutical companies. Prior to joining VeraSci, he was Director of Product Development at the world’s largest CRO, where his products received numerous industry awards and recognition for excellence and innovation. In his role as Vice President of Product Development, Mr. Clayton manages the development of our technology products and solutions. He is a Certified Scrum Master and received his BS in Computer Science from Ramapo State College.

Jenna Piunti

VP, Program Development
Read Bio
Jenna Piunti

Jenna Piunti

VP, Program Development

Jenna Piunti has been with VeraSci since 2009, and her leadership has been instrumental to the growth and success of the company. In her role as Vice President of Program Development, Ms. Piunti serves as the primary point of contact for project initiation, including contract execution, operational planning, and outsource partnering. She also provides oversight for key business development activities and provides supervision to our project management team. Ms. Piunti has extensive project management experience in Phase II and Phase III clinical trials, with a special emphasis on international trials in Asia and South America. Ms. Piunti received her BA in English from Siena College.

Trina Walker, RN

VP, Clinical Assessment
Read Bio
Trina Walker, RN

Trina Walker, RN

VP, Clinical Assessment

Trina Walker is a clinical assessment specialist and project manager with more than 15 years of experience in the mental health field. In addition to direct practice work with patients, she has held research positions at Duke University Medical Center and John Umstead Hospital where she investigated neurocognition in severe mental illness. Ms. Walker has supervised data collection for numerous domestic and international multisite clinical trials, including the CATIE schizophrenia and dementia trials. She has also worked alongside Dr. Keefe in developing several cognitive instruments, including the Brief Assessment of Cognition in Schizophrenia (BACS), and the Schizophrenia Cognition Rating Scale (SCoRS). In her role as Vice President of Clinical Assessment, Ms. Walker is responsible for overseeing all aspects of clinical data review, data quality assurance and training and for managing the scientific and operational execution of several active clinical trials. She received her BA in Rehabilitation Therapy and AD in Nursing from the University of North Carolina at Chapel Hill.

Sybil Fortner, MA

Senior Director, Clinical Assessments
Read Bio
Sybil Fortner, MA

Sybil Fortner, MA

Senior Director, Clinical Assessments

Sybil Fortner is Senior Director of Clinical Assessments at VeraSci. She reviews clinical data for multiple trials, assists with creating training plans for clinical staff, allocating clinical duties and ensuring that clinical staff (including Local Language Experts) are adequately trained and calibrated on the necessary clinical assessments. Prior to VeraSci, Ms. Fortner worked as a Senior Clinical Rater for Collaborative Neuroscience Network, LLC administering diagnostic and psychiatric symptom rating scales to adults participating in Phase I-IV psychiatric clinical trials. Sybil graduated with a Master’s Degree in Forensic Psychology from the University of Denver.

Susan Lloyd

VP, Operations and Global Language Solutions
Read Bio
Susan Lloyd

Susan Lloyd

VP, Operations and Global Language Solutions

Susan Lloyd is responsible for managing the development and growth of VeraSci’s Global Language Solutions. She leads the division’s operational, business development and quality control functions. Ms. Lloyd brings over 25 years of management experience in business development, strategic planning, program administration and financial and operations management in the consulting field. Ms. Lloyd has overseen projects for local, state and federal governments, educational institutions, national associations and private industry. Ms. Lloyd has been at VeraSci for the last seven years. Prior to joining VeraSci, she was a Vice President of Business for a national consulting firm dedicated to furthering higher education. Ms. Lloyd holds a Bachelor of Business Administration degree from the University of Mississippi.

Hampton Corley

Chief Commercial Officer
Read Bio
Hampton Corley

Hampton Corley

Chief Commercial Officer

As Chief Commercial Officer, Hampton is responsible for communicating to the broader CNS sponsor market VeraSci’s scientific, technologic, and customer-centric focus. Hampton joined VeraSci after hearing unanimous enthusiasm from VeraSci’s existing sponsor clients. “The recurring themes were the superiority of the customer experience and their trust in VeraSci,” he says. “Our scientific service excellence addresses sponsor endpoint challenges and expedites speed to signal.” Before joining VeraSci, Hampton spent eleven years in the lead commercial role at Clinipace during the company’s scale to a global CRO. Prior to that, he was at PSIMedica, a health information technology division of BioReference Laboratories, where he was responsible for software service licensing and revenue growth.

Josh Spiegel

VP, Business Strategy
Read Bio
Josh Spiegel

Josh Spiegel

VP, Business Strategy

Josh Spiegel has over 20 years of experience in finance and corporate advisory, with a strong background in healthcare, business services, and technology. Prior to joining VeraSci, he was a founding partner and Principal at Cypress Associates LLC, a New York based Investment Banking firm, where he was responsible for a broad range of transactions including mergers and acquisitions, restructurings, and equity offerings. Before joining Cypress, Mr. Spiegel was an Investment Banking Analyst in the technology group at CIBC World Markets. In his role as Vice President of Business Strategy, Mr. Spiegel leverages his experience to provide strategic planning and oversight of commercial operations, including the development of Pathway and positioning the company for growth. He received his BA in Economics and Public Policy from Duke University and holds the Chartered Financial Analyst® designation.

Shane Baldwin

VP, Quality Assurance and Compliance
Read Bio
Shane Baldwin

Shane Baldwin

VP, Quality Assurance and Compliance

Shane Baldwin has over 25 years of experience in clinical trial research. He started his career in Data Management and held various positions in Information Technology, Regulatory, and Quality Assurance departments at Contract and Academic Research Organizations. Prior to joining VeraSci, he was Associate Director of QA at a pharmaceutical company. In his role as Vice President of Quality Assurance and Compliance at VeraSci, Mr. Baldwin oversees the development and maintenance of a comprehensive Quality Assurance program that includes compliance, training, auditing, documentation and QA support of sponsor projects to ensure adherence to global regulations. He received his BA in English from North Carolina State University.

Richard Keefe, PhD

Richard Keefe, PhD

Co-Founder & CEO

Read Bio »

Dr. Richard Keefe co-founded NeuroCog Trials, now VeraSci, in an effort to bring transformative, scientifically rigorous innovation to neurocognitive data collection in clinical trials. He has over 25 years of experience in clinical psychology, neuroscience, and drug development, and is globally recognized for his expertise in novel strategies for measuring treatment-related changes in human performance and behavior. As Chief Executive Officer, Dr. Keefe provides leadership across our scientific, technology, operational, and quality assurance teams, and maintains supportive relationships with key industry leaders and scientific advisors. Dr. Keefe’s responsive, engaged leadership and his commitment to scientific integrity are at the core of our company culture and service model. In addition to his role at VeraSci, Dr. Keefe is Professor of Psychiatry, Psychology and Neurosciences at Duke University Medical Center, and serves on the Editorial Board of Psychological Medicine, Schizophrenia Research, and Innovations in Clinical Neuroscience. He is a Fellow of the American College of Neuropsychopharmacology, and on the Scientific Board of the Brain and Behavior Research Foundation. Dr. Keefe was President of the International Society for CNS Clinical Trials and Methodology from 2012 to 2014. He has published over 250 peer-reviewed scientific papers on cognition and CNS disorders. He received his bachelor’s degree in psychology from Princeton University and received his PhD in clinical psychology from NYU. He completed his clinical psychology internship at Yale University School of Medicine.

x
Caren Gadigian

Caren Gadigian

Co-Founder & President

Read Bio »

Caren Gadigian co-founded NeuroCog Trials, now VeraSci, in 2004, bringing her extensive knowledge of finance and business to spearhead the company’s successful development and rapid expansion. She has over 20 years of experience working with private equity firms, providing investment management and operational expertise across a variety of industry sectors. As President, Ms. Gadigian is responsible for leading the company’s strategic growth and directing the standard of excellence that defines all company operations. With an incisive understanding of organizational development, she ensures that VeraSci has the best staff and the most effective services to achieve the greatest impact on therapeutic discovery.

x
Luca Pani, MD

Luca Pani, MD

VP, Regulatory Strategy and Market Access Innovation

Read Bio »

Dr. Luca Pani is former Director General of the Italian Medicines Agency (AIFA) and a globally recognized expert in psychiatry, pharmacology and molecular biology. As Vice President for Regulatory Strategy and Market Access Innovation, Dr. Pani guides the company’s development of innovative solutions for clinical trials methodologies and health value outcomes. During his tenure as Director General of AIFA, Dr. Pani pioneered several new approaches to drug approval, pricing, and reimbursement strategies by using advanced informatics to follow and certify real-world data. These models have now been adopted in many other countries. As a European regulator, Dr. Pani has been a leading figure for approval and scientific advice for CNS products and served as Chair of both the European Union Board Telematics Committee and of the European Risk Management Strategy Facilitation Group. He has authored or co-authored hundreds of publications and served on the editorial boards of many scientific journals, including Clinical Neuropsychiatry. He is Professor of Clinical Psychiatry at the University of Miami. Dr. Pani earned his medical degree from the University of Cagliari, psychiatry degree from the University of Naples and completed post-doctoral training in molecular biology and pharmacology at the University of Illinois at Chicago and Georgetown University.

x
Kathleen Anne Welsh-Bohmer, PhD, ABPP

Kathleen Anne Welsh-Bohmer, PhD, ABPP

VP, Neurodegenerative Disorders

Read Bio »

For more than 25 years, Dr. Kathleen Anne Welsh-Bohmer’s research activities have been focused around developing effective prevention and treatment strategies to eliminate the onset of cognitive disorders occurring in later life. As one of the true leaders in Alzheimer’s Disease scientific research, Dr. Welsh-Bohmer brings vast expertise to VeraSci. As Vice President for Neurodegenerative Disorders at VeraSci, she leads a team of scientists and operational experts in developing new tools for assessing cognitive and clinical changes and supporting clinical trials in MCI, Alzheimer’s disease and other neurological and age-related disorders. Most recently, Dr. Welsh-Bohmer provided oversight of the neuropsychology scientific operations of a Phase III global clinical trial to delay the onset of Alzheimer’s disease entitled the “TOMMORROW” study. The methods her team developed for this study filled an information void and had implications for accelerating global clinical trials in Alzheimer’s disease prevention. Dr. Welsh-Bohmer’s work as Director of the Joseph and Kathleen Bryan Alzheimer’s Disease Research Center (Bryan ADRC) at Duke University Medical Center was centered around discovering the biological basis of Alzheimer’s disease and developing methods to enhance early diagnosis and speed drug discovery. In addition to her current work at VeraSci, she serves as the Director of Alzheimer’s Disease Clinical Trials within the Duke Clinical Research Institute and is a Professor of Psychiatry with a secondary appointment in the Department of Neurology at Duke University. Therapeutic Focus: Alzheimer's Disease

x
Alexandra Atkins, PhD

Alexandra Atkins, PhD

VP, Scientific Development

Read Bio »

Dr. Alexandra Atkins is a psychologist and cognitive neuroscientist with expertise in cognitive assessment, clinical trial methodology, and the cognitive neuroscience of memory. Over the past seven years, she has worked alongside Dr. Keefe to spearhead the development of valid and reliable assessments of cognition and function for use in CNS clinical trials and clinical practice. As Vice President of Scientific Development, Dr. Atkins provides scientific oversite to VeraSci project teams across CNS indications and serves as PI on several ongoing technology-based research initiatives supported by the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA). Dr. Atkins has received National Research Service Awards from both NIMH and NIA to support research using cognitive testing in conjunction with functional neuroimaging techniques to examine the cognitive and neural mechanisms of memory distortion and executive functioning. Her current interests include the strategic use of innovative technology to support valid clinical ratings in clinical trials and improving assessment of subtle functional impairments in prodromal MCI/AD. Dr. Atkins earned her PhD in psychology from the University of Michigan and completed her research fellowship at Duke University’s Center for Cognitive Neuroscience. Therapeutic Focus: CNS Disorders

x
William P. Horan, PhD

William P. Horan, PhD

VP, Clinical Science

Read Bio »

As a Vice President of Clinical Science, Dr. Horan uses his expertise in cognition, social neuroscience, and symptom assessment to provide scientific and operational support for clinical trials in psychiatric disorders. Prior to joining VeraSci, Dr. Horan was Professor-in-Residence in the Department of Psychiatry & Biobehavioral Sciences at UCLA and Chief of the Psychosis Section at the VA Greater Los Angeles Healthcare System. Over the past 20 years, his clinical research has focused on understanding and developing treatments for motivational, social cognitive, and neurocognitive disturbances that impact functional outcomes in schizophrenia and other neuropsychiatric conditions. Specific interests include negative symptoms, translational affective and social cognitive neuroscience research, and development of novel physiological and behavioral tasks for use as endpoints in clinical trials. His research has been funded by NIMH, VA, and foundation grants, and he served as a Principal Investigator in the NIMH Collaboration to Advance Negative Symptom Assessment in Schizophrenia. He is on the Editorial Boards of Schizophrenia Bulletin, Schizophrenia Research: Cognition, and Journal of Abnormal Psychology (Associate Editor). He has over 130 peer-reviewed articles and has been recognized as a Thomson Reuters Highly Cited Researcher (Top 1% in Psychiatry/ Psychology). Therapeutic Focus: Schizophrenia

x
Mark Skeen, MD

Mark Skeen, MD

Senior Medical Scientist

Read Bio »

Dr. Mark Skeen is a Senior Medical Scientist at VeraSci. Dr. Skeen is a neurologist with broad clinical training and experience. He is board certified in Internal Medicine, Neurology, and Clinical Neurophysiology and has broad clinical experience in neurology clinical trials in several disease states. He has over 30 years of clinical experience from general internal medicine to neurology subspecialty care and for the past 15 years his focus has been multiple sclerosis and related autoimmune conditions. He is recognized as a thought leader in multiple sclerosis and has been recognized for both clinical and teaching expertise. Dr. Skeen also serves as an Associate Professor of Neurology at Duke University Medical Center and is the head of the division of Multiple Sclerosis and Neuroimmunology. He is a Fellow of the American College of Physicians and the American Academy of Neurology. He has many longstanding partnerships throughout the pharmaceutical industry and brings a distinctly clinical neurologic perspective to VeraSci. Therapeutic Focus: Multiple Sclerosis

x
Heather Snyder, PhD

Heather Snyder, PhD

Senior Director, Neurosciences

Read Bio »

Dr. Heather Snyder is Senior Director of Neurosciences at VeraSci. She provides scientific and clinical input to the development of training materials for clinical assessments utilized in clinical trials for neurologic and psychiatric indications. Dr. Snyder and the scientific team also provide consultation regarding protocol design and outcome measures, as well as clinical development pathways. Additional responsibilities include provision of scientific input for data review and analyses, business development, and development of assessments on VeraSci’s eCOA platform, Pathway. Before joining VeraSci, Dr. Snyder spent over 13 years in program leadership roles for neuroscience clinical development, within pharmaceutical clinical research departments. As such, she held positions within key biopharmaceutical companies, including Astra Merck Inc., Astra AB, Merck & Co., Cephalon, Inc., and Astra-Zeneca. Dr. Snyder led development programs for following neuroscience indications: Generalized Anxiety Disorder, Post-traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder, Major Depressive Disorder, Multiple Sclerosis, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis. Dr. Snyder obtained her BA in Philosophy from Georgetown University, and her PhD in Clinical Psychology, with a focus in Neuropsychology, from George Mason University. Her Post-Doctoral Fellowship work was done at the University of Pennsylvania. Therapeutic Focus: Parkinson's Disease, Multiple Sclerosis, Rare & Orphan Diseases

x
Adam W. Vaughan, PhD

Adam W. Vaughan, PhD

Senior Director, Psychological Assessments

Read Bio »

Dr. Adam Vaughan is Senior Director of Psychological Assessments at VeraSci. He is one of our project managers in the VeraSci Innovation Lab, which focuses on R&D of our proprietary tools. Adam also represents our company at various conferences and works on our rare and orphan disease studies. Prior to joining the team at VeraSci, Adam worked as a school psychologist in the public-school system, assessing and evaluating a full range of children and adolescents with special needs and behavioral issues. Adam received his bachelor’s in Psychology from the University of North Carolina at Chapel Hill and his Doctoral Degree in Psychology and Psychometrics from Auburn University. Therapeutic Focus: Childhood Disorders, Rare & Orphan Diseases

x
Antonio Hernandez, PsyD

Antonio Hernandez, PsyD

Senior Clinical Director, Neurodegenerative Disorders

Read Bio »

Dr. Antonio Hernandez is Senior Clinical Director of Neurodegenerative Disorders at VeraSci. He participates in the development and use of innovative new technologies that assess cognition in Alzheimer’s disease and aging. He also assists in developing and validating new test batteries, reviewing, analyzing and interpreting cognitive test data, and oversees neurocognitive rater certification and data quality control for multi-site pharmaceutical company trials. Other key activities include development of strategic objectives that support the company’s research and development strategies along with establishing strategic partnerships and alliances. Dr. Hernandez came to VeraSci with over 15 years of clinical research experience across several CNS therapeutic areas. His vast industry experience, exceptional degree of sustained ingenuity, creativity and resourcefulness has been instrumental in shaping the course of many clinical trials in CNS. He has a deep understanding of the clinical as well as operational challenges facing global clinical trials today and has worked closely within multidisciplinary team environments, including business development and marketing. Fluent in Spanish, he has also contributed to the translation and development of eCOA in the assessment of dementia and pre-MCI subjects. Therapeutic Focus: Alzheimer's Disease

x
Timothy Clayton

Timothy Clayton

VP, Product Development

Read Bio »

Tim Clayton has been developing and delivering successful software products, devices and data solutions for over 25 years, with more than 13 years focused in clinical research and medical device industries. His deep knowledge of C-DISC data standards, clinical data management processes, database, cloud and software development technologies was acquired through hands on building and management of clinical data warehouses, analytics and B2B solutions supporting the world’s top pharmaceutical companies. Prior to joining VeraSci, he was Director of Product Development at the world’s largest CRO, where his products received numerous industry awards and recognition for excellence and innovation. In his role as Vice President of Product Development, Mr. Clayton manages the development of our technology products and solutions. He is a Certified Scrum Master and received his BS in Computer Science from Ramapo State College.

x
Jenna Piunti

Jenna Piunti

VP, Program Development

Read Bio »

Jenna Piunti has been with VeraSci since 2009, and her leadership has been instrumental to the growth and success of the company. In her role as Vice President of Program Development, Ms. Piunti serves as the primary point of contact for project initiation, including contract execution, operational planning, and outsource partnering. She also provides oversight for key business development activities and provides supervision to our project management team. Ms. Piunti has extensive project management experience in Phase II and Phase III clinical trials, with a special emphasis on international trials in Asia and South America. Ms. Piunti received her BA in English from Siena College.

x
Trina Walker, RN

Trina Walker, RN

VP, Clinical Assessment

Read Bio »

Trina Walker is a clinical assessment specialist and project manager with more than 15 years of experience in the mental health field. In addition to direct practice work with patients, she has held research positions at Duke University Medical Center and John Umstead Hospital where she investigated neurocognition in severe mental illness. Ms. Walker has supervised data collection for numerous domestic and international multisite clinical trials, including the CATIE schizophrenia and dementia trials. She has also worked alongside Dr. Keefe in developing several cognitive instruments, including the Brief Assessment of Cognition in Schizophrenia (BACS), and the Schizophrenia Cognition Rating Scale (SCoRS). In her role as Vice President of Clinical Assessment, Ms. Walker is responsible for overseeing all aspects of clinical data review, data quality assurance and training and for managing the scientific and operational execution of several active clinical trials. She received her BA in Rehabilitation Therapy and AD in Nursing from the University of North Carolina at Chapel Hill.

x
Sybil Fortner, MA

Sybil Fortner, MA

Senior Director, Clinical Assessments

Read Bio »

Sybil Fortner is Senior Director of Clinical Assessments at VeraSci. She reviews clinical data for multiple trials, assists with creating training plans for clinical staff, allocating clinical duties and ensuring that clinical staff (including Local Language Experts) are adequately trained and calibrated on the necessary clinical assessments. Prior to VeraSci, Ms. Fortner worked as a Senior Clinical Rater for Collaborative Neuroscience Network, LLC administering diagnostic and psychiatric symptom rating scales to adults participating in Phase I-IV psychiatric clinical trials. Sybil graduated with a Master’s Degree in Forensic Psychology from the University of Denver.

x
Susan Lloyd

Susan Lloyd

VP, Operations and Global Language Solutions

Read Bio »

Susan Lloyd is responsible for managing the development and growth of VeraSci’s Global Language Solutions. She leads the division’s operational, business development and quality control functions. Ms. Lloyd brings over 25 years of management experience in business development, strategic planning, program administration and financial and operations management in the consulting field. Ms. Lloyd has overseen projects for local, state and federal governments, educational institutions, national associations and private industry. Ms. Lloyd has been at VeraSci for the last seven years. Prior to joining VeraSci, she was a Vice President of Business for a national consulting firm dedicated to furthering higher education. Ms. Lloyd holds a Bachelor of Business Administration degree from the University of Mississippi.

x
Hampton Corley

Hampton Corley

Chief Commercial Officer

Read Bio »

As Chief Commercial Officer, Hampton is responsible for communicating to the broader CNS sponsor market VeraSci’s scientific, technologic, and customer-centric focus. Hampton joined VeraSci after hearing unanimous enthusiasm from VeraSci’s existing sponsor clients. “The recurring themes were the superiority of the customer experience and their trust in VeraSci,” he says. “Our scientific service excellence addresses sponsor endpoint challenges and expedites speed to signal.” Before joining VeraSci, Hampton spent eleven years in the lead commercial role at Clinipace during the company’s scale to a global CRO. Prior to that, he was at PSIMedica, a health information technology division of BioReference Laboratories, where he was responsible for software service licensing and revenue growth.

x
Josh Spiegel

Josh Spiegel

VP, Business Strategy

Read Bio »

Josh Spiegel has over 20 years of experience in finance and corporate advisory, with a strong background in healthcare, business services, and technology. Prior to joining VeraSci, he was a founding partner and Principal at Cypress Associates LLC, a New York based Investment Banking firm, where he was responsible for a broad range of transactions including mergers and acquisitions, restructurings, and equity offerings. Before joining Cypress, Mr. Spiegel was an Investment Banking Analyst in the technology group at CIBC World Markets. In his role as Vice President of Business Strategy, Mr. Spiegel leverages his experience to provide strategic planning and oversight of commercial operations, including the development of Pathway and positioning the company for growth. He received his BA in Economics and Public Policy from Duke University and holds the Chartered Financial Analyst® designation.

x
Shane Baldwin

Shane Baldwin

VP, Quality Assurance and Compliance

Read Bio »

Shane Baldwin has over 25 years of experience in clinical trial research. He started his career in Data Management and held various positions in Information Technology, Regulatory, and Quality Assurance departments at Contract and Academic Research Organizations. Prior to joining VeraSci, he was Associate Director of QA at a pharmaceutical company. In his role as Vice President of Quality Assurance and Compliance at VeraSci, Mr. Baldwin oversees the development and maintenance of a comprehensive Quality Assurance program that includes compliance, training, auditing, documentation and QA support of sponsor projects to ensure adherence to global regulations. He received his BA in English from North Carolina State University.

x

VeraSci’s Scientific Advisors

Ralph H. B. Benedict, PhD

Professor of Neurology, Psychiatry and Psychology Department of Neurology, University at Buffalo School of Medicine and Biomedical Sciences State University of New York (SUNY)

Robert Bilder, PhD

A Clinical Neuropsychologist who has been actively engaged for over 30 years in research on the neuroanatomic and neuropsychological bases of major mental illnesses. He is currently Chief of Medical Psychology – Neuropsychology, and Senior Research Scientist, Ahmanson-Lovelace Brain Mapping Center, UCLA Neuropsychiatric Institute and Hospital

Jeff Cummings, MD

Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio; Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Terry Goldberg, PhD

Director of Research in Neurocognition at the Litwin-Zucker Alzheimer’s Disease Center at the Albert Einstein College of Medicine. Prior to his current position, he directed a neurocognitive unit at the NIMH

John Harrison, PhD

Associate Professor at the Alzheimer Centre, VU Medical Centre, Amsterdam and Principal Consultant at Metis Cognition Ltd.

Phil Harvey, PhD

Professor of Psychiatry & Behavioral Sciences and Director, Division of Psychology, Department of Psychiatry & Behavioral Sciences at Miami University

Daniel Laskowitz, MD

Professor of Psychiatry and Neurology, Duke University Medical Center, Director of Neuroscience Medicine, Duke Clinical Research Institute, Director, Duke Neurovascular Laboratories

Steve Marder, MD

Professor and Vice Chair of the Department of Psychiatry at UCLA; Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs; Director of the Section on Psychosis at the UCLA Neuropsychiatric Institute

Dave Rubinow, MD

Assad Meymandi Distinguished Professor and Chair of Psychiatry; Professor of Medicine; Director, UNC Innovation and Health Care System Transformation; and Director, UNC Center for Women’s Mood Disorders

Mary Sano, PhD

Professor of Psychiatry and the Director of the Alzheimer’s Disease Research at Mount Sinai School of Medicine; Director of Research and Development at the Bronx Veterans Administration Hospital

Laurie Sanders, PhD

Assistant professor of Psychiatry and Neurology, Duke University Medical Center, Director of Neuroscience Medicine, Duke Clinical Research Institute, Director, Duke Neurovascular Laboratories

John Sweeney, PhD

Professor of Psychiatry and Pediatrics, and Vice Chair for Clinical Research at the University of Texas Southwestern, focusing on psychiatric disorders including schizophrenia and mood disorder and neurodevelopmental disorders including autism and fragile X syndrome. He is also currently Visiting Professor of Radiology at Szechuan University in Chengdu, China

Dave Walling, PhD

Chief Executive and Clinical Officer at Collaborative Neuroscience Network, Inc.

Bianca Weinstock-Guttman

MD Professor of Neurology, Jacobs Neurological Institute, SUNY Buffalo School of Medicine Buffalo